Adam L Boxer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2976977/publications.pdf

Version: 2024-02-01

160 papers	22,878 citations	16451 64 h-index	9589 142 g-index
167 all docs	167 docs citations	167 times ranked	21601 citing authors

#	Article	IF	Citations
1	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. Brain, 2022, 145, 1079-1097.	7.6	30
2	Lower White Matter Volume and Worse Executive Functioning Reflected in Higher Levels of Plasma GFAP among Older Adults with and Without Cognitive Impairment. Journal of the International Neuropsychological Society, 2022, 28, 588-599.	1.8	14
3	Current directions in tau research: Highlights from Tau 2020. Alzheimer's and Dementia, 2022, 18, 988-1007.	0.8	42
4	The contribution of behavioral features to caregiver burden in FTLD spectrum disorders. Alzheimer's and Dementia, 2022, 18, 1635-1649.	0.8	9
5	Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Neurology, 2022, 98, .	1.1	49
6	Clinical Trial Development in Frontotemporal Lobar Degeneration. , 2022, , 216-231.		0
7	Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. Lancet Neurology, The, 2022, 21, 258-272.	10.2	63
8	Subcortical Neuronal Correlates of Sleep in Neurodegenerative Diseases. JAMA Neurology, 2022, 79, 498.	9.0	20
9	A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. Movement Disorders, 2022, 37, 1265-1271.	3.9	9
10	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Reports Medicine, 2022, 3, 100607.	6.5	21
11	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Network Open, 2022, 5, e229588.	5.9	18
12	Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia. Neurology, 2022, , 10.1212/WNL.0000000000200582.	1.1	0
13	Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology. Neurology, 2022, 99, .	1.1	10
14	Right temporal degeneration and socioemotional semantics: semantic behavioural variant frontotemporal dementia. Brain, 2022, 145, 4080-4096.	7.6	34
15	Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	16
16	Brain volumetric deficits in MAPT mutation carriers: a multisite study. Annals of Clinical and Translational Neurology, 2021, 8, 95-110.	3.7	21
17	Diagnostic Accuracy of Amyloid versus ¹⁸Fâ€Fluorodeoxyglucose Positron Emission Tomography in <scp>Autopsyâ€Confirmed</scp> Dementia. Annals of Neurology, 2021, 89, 389-401.	5.3	34
18	Development and validation of the Uniform Data Set (v3.0) executive function composite score (UDS3â€EF). Alzheimer's and Dementia, 2021, 17, 574-583.	0.8	15

#	Article	IF	Citations
19	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	6.4	27
20	The Frontotemporal Dementia Prevention Initiative: Linking Together Genetic Frontotemporal Dementia Cohort Studies. Advances in Experimental Medicine and Biology, 2021, 1281, 113-121.	1.6	3
21	FTLD Treatment: Current Practice and Future Possibilities. Advances in Experimental Medicine and Biology, 2021, 1281, 297-310.	1.6	9
22	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, 17, 1329-1341.	0.8	34
23	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. JAMA Network Open, 2021, 4, e211290.	5.9	12
24	Comorbid neuropathological diagnoses in early versus late-onset Alzheimerâ€™s disease. Brain, 2021, 144, 2186-2198.	7.6	100
25	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.1	52
26	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. Cortex, 2021, 139, 99-115.	2.4	12
27	Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care. Frontiers in Neurology, 2021, 12, 694872.	2.4	29
28	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	9.0	148
29	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nature Medicine, 2021, 27, 1451-1457.	30.7	63
30	Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell, 2021, 184, 4651-4668.e25.	28.9	97
31	Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity. JAMA Neurology, 2021, 78, 1345.	9.0	109
32	Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency. JAMA Network Open, 2021, 4, e2125584.	5.9	18
33	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	10.2	220
34	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology, 2021, 96, e671-e683.	1.1	84
35	Disease progression models of familial frontotemporal lobar degeneration and the temporal ordering of biomarker changes in an international cohort. Alzheimer's and Dementia, 2021, 17, .	0.8	1
36	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.8	32

#	Article	IF	Citations
37	Evidence of corticofugal tau spreading in patients with frontotemporal dementia. Acta Neuropathologica, 2020, 139, 27-43.	7.7	29
38	Cognitive decline on the Repeatable Battery for the Assessment of Neuropsychological Status in progressive supranuclear palsy. Clinical Neuropsychologist, 2020, 34, 529-540.	2.3	5
39	4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathologica, 2020, 139, 63-77.	7.7	89
40	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.8	38
41	Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 215.	9.0	81
42	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. Alzheimer's and Dementia, 2020, 16, 22-36.	0.8	32
43	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. Alzheimer's and Dementia, 2020, 16, 131-143.	0.8	45
44	Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy. Molecular Neurodegeneration, 2020, 15, 2.	10.8	69
45	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
46	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.8	27
47	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism and Related Disorders, 2020, 79, 121-126.	2.2	11
48	Four-Repeat Tauopathies: Current Management and Future Treatments. Neurotherapeutics, 2020, 17, 1563-1581.	4.4	24
49	Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage1. Journal of Alzheimer's Disease, 2020, 78, 265-276.	2.6	43
50	Lack of Association Between the CCR5-delta32 Polymorphism and Neurodegenerative Disorders. Alzheimer Disease and Associated Disorders, 2020, 34, 244-247.	1.3	11
51	Associations Between Amantadine Usage, Gait, and Cognition in PSP: A post-hoc Analysis of the Davunetide Trial. Frontiers in Neurology, 2020, 11, 606925.	2.4	6
52	Tau therapeutics: Clinical development status and future directions. Alzheimer's and Dementia, 2020, 16, e044852.	0.8	0
53	18F-flortaucipir PET to autopsy comparisons in Alzheimerâ€™s disease and other neurodegenerative diseases. Brain, 2020, 143, 3477-3494.	7.6	100
54	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. JAMA Network Open, 2020, 3, e2022847.	5.9	19

#	Article	IF	Citations
55	Targeting tau: Clinical trials and novel therapeutic approaches. Neuroscience Letters, 2020, 731, 134919.	2.1	63
56	Longitudinal structural and metabolic changes in frontotemporal dementia. Neurology, 2020, 95, e140-e154.	1.1	39
57	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurology, 2020, 77, 632.	9.0	80
58	Progressive supranuclear palsy and primary lateral sclerosis secondary to globular glial tauopathy: a case report and a practical theoretical framework for the clinical prediction of this rare pathological entity. Neurocase, 2020, 26, 91-97.	0.6	12
59	Diagnostic value of plasma phosphorylated tau181 in Alzheimerâ€™s disease and frontotemporal lobar degeneration. Nature Medicine, 2020, 26, 387-397.	30.7	471
60	Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS. Alzheimer's and Dementia, 2020, 16, 71-78.	0.8	33
61	Utility of the global CDR^{Â®} plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. Alzheimer's and Dementia, 2020, 16, 106-117.	0.8	81
62	<scp>Openâ€Label</scp> Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2020, 7, 440-447.	1.5	34
63	Revised Self-Monitoring Scale. Neurology, 2020, 94, e2384-e2395.	1.1	23
64	Digital Cognitive Assessments for Dementia: Digital assessments may enhance the efficiency of evaluations in neurology and other clinics. Practical Neurology, 2020, 2020, 24-45.	0.5	1
65	Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 338-346.	3.7	22
66	Peripheral Innate Immune Activation Correlates With Disease Severity in GRN Haploinsufficiency. Frontiers in Neurology, 2019, 10, 1004.	2.4	7
67	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	3.1	14
68	Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials. Brain, 2019, 142, 443-459.	7.6	65
69	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	9.0	455
70	Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurology, The, 2019, 18, 549-558.	10.2	108
71	Neuropathological correlates of structural and functional imaging biomarkers in 4-repeat tauopathies. Brain, 2019, 142, 2068-2081.	7.6	30
72	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	3.9	93

#	Article	IF	Citations
73	Thalamo-cortical network hyperconnectivity in preclinical progranulin mutation carriers. NeuroImage: Clinical, 2019, 22, 101751.	2.7	30
74	Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological Status. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 469-475.	1.3	12
75	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
76	O4â€02â€01: PHASE 2A RANDOMIZED, DOUBLEâ€BLIND, PLACEBOâ€CONTROLLED TRIAL OF THE HISTONE DEACETYLASE INHIBITOR (HDACI), FRMâ€0334, IN ASYMPTOMATIC CARRIERS OF, OR PATIENTS WITH FRONTOTEMPORAL LOBAR DEGENERATION (FTLD) DUE TO, PROGRANULIN GENE MUTATIONS. Alzheimer's and Dementia, 2019, 15, P1231.	0.8	4
77	Frequency of the TREM2 R47H Variant in Various Neurodegenerative Disorders. Alzheimer Disease and Associated Disorders, 2019, 33, 327-330.	1.3	6
78	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism and Related Disorders, 2019, 60, 138-145.	2.2	7
79	Multisite study of the relationships between antemortem [¹¹C]PIBâ€PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2019, 15, 205-216.	0.8	155
80	Therapeutic trial design for frontotemporal dementia and related disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 412-423.	1.9	21
81	Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 851-858.	1.9	37
82	Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration. Neurology, 2018, 90, e1047-e1056.	1.1	36
83	CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology, 2018, 90, e273-e281.	1.1	75
84	Associations between [¹⁸ F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology, 2018, 90, e282-e290.	1.1	113
85	Retraining speech production and fluency in non-fluent/agrammatic primary progressive aphasia. Brain, 2018, 141, 1799-1814.	7.6	79
86	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
87	O2â€14â€06: DIFFERENCES BETWEEN SPORADIC AND FAMILIAL BEHAVIORAL VARIANT FTD IN ADVANCING RESEARCH AND TREATMENT FOR FTLD (ARTFL) CLINICAL RESEARCH CONSORTIUM. Alzheimer's and Dementia, 2018, 14, P658.	0.8	0
88	Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Annals of Clinical and Translational Neurology, 2018, 5, 1250-1263.	3.7	40
89	Tau Mutations as a Novel Risk Factor for Cancerâ€”Letter. Cancer Research, 2018, 78, 6523-6524.	0.9	2
90	Discriminative Accuracy of [¹⁸F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	7.4	298

#	Article	IF	Citations
91	Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. Molecular Neurodegeneration, 2018, 13, 41.	10.8	77
92	Altered topology of the functional speech production network in non-fluent/agrammatic variant of PPA. Cortex, 2018, 108, 252-264.	2.4	41
93	Genome-wide association study identifies MAPT locus influencing human plasma tau levels. Neurology, 2017, 88, 669-676.	1.1	33
94	Regional correlations between [11 C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. NeuroImage: Clinical, 2017, 13, 130-137.	2.7	50
95	Frontotemporal dementia with the V337M MAPT mutation. Neurology, 2017, 88, 758-766.	1.1	76
96	Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathologica, 2017, 133, 825-837.	7.7	90
97	Dataâ€driven regions of interest for longitudinal change in three variants of frontotemporal lobar degeneration. Brain and Behavior, 2017, 7, e00675.	2.2	22
98	Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Science Translational Medicine, 2017, 9, .	12.4	78
99	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	3.9	121
100	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Movement Disorders, 2017, 32, 955-971.	3.9	179
101	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	3.9	1,402
102	Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. Movement Disorders, 2017, 32, 842-852.	3.9	52
103	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurology, The, 2017, 16, 552-563.	10.2	303
104	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	12.4	179
105	Longitudinal white matter change in frontotemporal dementia subtypes and sporadic late onset Alzheimer's disease. NeuroImage: Clinical, 2017, 16, 595-603.	2.7	45
106	Distinct spatiotemporal patterns of neuronal functional connectivity in primary progressive aphasia variants. Brain, 2017, 140, 2737-2751.	7.6	53
107	Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain, 2017, 140, 3329-3345.	7.6	226
108	An 8â€week, openâ€label, doseâ€finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 507-512.	3.7	32

#	Article	IF	Citations
109	Advancing functional dysconnectivity and atrophy in progressive supranuclear palsy. NeuroImage: Clinical, 2017, 16, 564-574.	2.7	26
110	ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature, 2017, 549, 523-527.	27.8	852
111	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
112	A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction. Brain, 2017, 140, 1128-1146.	7.6	84
113	Sleepless Night and Day, the Plight of Progressive Supranuclear Palsy. Sleep, 2017, 40, .	1.1	35
114	Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study. PLoS ONE, 2016, 11, e0157218.	2.5	40
115	Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale. Movement Disorders, 2016, 31, 1574-1577.	3.9	10
116	Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration. JAMA Neurology, 2016, 73, 733.	9.0	131
117	Network-driven plasma proteomics expose molecular changes in the Alzheimerâ€™s brain. Molecular Neurodegeneration, 2016, 11, 31.	10.8	34
118	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism and Related Disorders, 2016, 28, 41-48.	2.2	33
119	Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease. FASEB Journal, 2016, 30, 4141-4148.	0.5	281
120	Therapy and clinical trials in frontotemporal dementia: past, present, and future. Journal of Neurochemistry, 2016, 138, 211-221.	3.9	109
121	Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Annals of Clinical and Translational Neurology, 2016, 3, 216-225.	3.7	163
122	Rest-activity rhythm disruption in progressive supranuclear palsy. Sleep Medicine, 2016, 22, 50-56.	1.6	18
123	Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e301.	6.0	78
124	Distinct Subtypes of Behavioral Variant Frontotemporal Dementia Based on Patterns of Network Degeneration. JAMA Neurology, 2016, 73, 1078.	9.0	115
125	Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology, 2016, 87, 2016-2025.	1.1	65
126	Targeting tauopathies for therapeutic translation. Nature Reviews Neurology, 2016, 12, 74-76.	10.1	21

#	Article	IF	Citations
127	Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. Neurology, 2016, 86, 600-610.	1.1	73
128	Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology, 2015, 85, 40-47.	1.1	355
129	Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain, 2015, 138, 2020-2033.	7.6	319
130	Oxytocin for frontotemporal dementia. Neurology, 2015, 84, 174-181.	1.1	83
131	Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimer's Research and Therapy, 2015, 7, 8.	6.2	32
132	Primary chronic traumatic encephalopathy in an older patient with late-onset AD phenotype. Neurology: Clinical Practice, 2015, 5, 475-479.	1.6	4
133	Divergent CSF Â alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 244-250.	1.9	101
134	At the interface of sensory and motor dysfunctions and Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 70-98.	0.8	420
135	Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Brain, 2014, 137, 3047-3060.	7.6	140
136	Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Annals of Neurology, 2014, 75, 116-126.	5.3	213
137	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	9.0	166
138	NIH EXAMINER: Conceptualization and Development of an Executive Function Battery. Journal of the International Neuropsychological Society, 2014, 20, 11-19.	1.8	190
139	Clinical Trials: Past, Current, and Future for Atypical Parkinsonian Syndromes. Seminars in Neurology, 2014, 34, 225-234.	1.4	19
140	The functional oculomotor network and saccadic cognitive control in healthy elders. NeuroImage, 2014, 95, 61-68.	4.2	27
141	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurology, The, 2014, 13, 676-685.	10.2	245
142	Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2013, 12, 149-156.	10.2	204
143	The advantages of frontotemporal degeneration drug development (partÂ2Âof frontotemporal) Tj ETQq1 1 0.784314 rgBT /Overlock	0.8	48
144	Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development. Alzheimer's and Dementia, 2013, 9, 176-188.	0.8	58

#	Article	IF	Citations
145	Criteria for the diagnosis of corticobasal degeneration. Neurology, 2013, 80, 496-503.	1.1	1,445
146	Patterns of Striatal Degeneration in Frontotemporal Dementia. Alzheimer Disease and Associated Disorders, 2013, 27, 74-83.	1.3	55
147	Intrinsic connectivity network disruption in progressive supranuclear palsy. Annals of Neurology, 2013, 73, 603-616.	5.3	88
148	Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Human Molecular Genetics, 2012, 21, 3500-3512.	2.9	198
149	Saccade Abnormalities in Autopsy-Confirmed Frontotemporal Lobar Degeneration and Alzheimer Disease. Archives of Neurology, 2012, 69, 509.	4.5	97
150	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron, 2011, 72, 245-256.	8.1	4,176
151	Clinicopathological correlations in corticobasal degeneration. Annals of Neurology, 2011, 70, 327-340.	5.3	367
152	Abhorring the vacuum: use of Alzheimerâ€™s disease medications in frontotemporal dementia. Expert Review of Neurotherapeutics, 2011, 11, 709-717.	2.8	47
153	Off-Label Medication Use in Frontotemporal Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2010, 25, 128-133.	1.9	57
154	An Open-label Study of Memantine Treatment in 3 Subtypes of Frontotemporal Lobar Degeneration. Alzheimer Disease and Associated Disorders, 2009, 23, 211-217.	1.3	110
155	Frontotemporal Dementia Treatment: Current Symptomatic Therapies and Implications of Recent Genetic, Biochemical, and Neuroimaging Studies. Alzheimer Disease and Associated Disorders, 2007, 21, S79-S87.	1.3	74
156	Patterns of Brain Atrophy That Differentiate Corticobasal Degeneration Syndrome From Progressive Supranuclear Palsy. Archives of Neurology, 2006, 63, 81.	4.5	315
157	Medial Versus Lateral Frontal Lobe Contributions to Voluntary Saccade Control as Revealed by the Study of Patients with Frontal Lobe Degeneration. Journal of Neuroscience, 2006, 26, 6354-6363.	3.6	85
158	Clinical Features of Frontotemporal Dementia. Alzheimer Disease and Associated Disorders, 2005, 19, S3-S6.	1.3	102
159	Frontotemporal lobar degeneration. , 2005, , 481-493.		1
160	Cinguloparietal Atrophy Distinguishes Alzheimer Disease From Semantic Dementia. Archives of Neurology, 2003, 60, 949.	4.5	106